The American College of Gastroenterology (ACG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. ACG, as an ACCME accredited provider, ensures balance, independence, objectivity, and scientific rigor in all of its directly and jointly provided education activities. All who are in a position to control the content of an education activity (including their spouse or partner) are required to disclose to ACG all relevant financial relationships in any amount occurring in the past 12 months with any commercial interest that may create a conflict of interest related to the subject matter of an education activity. Safeguards against commercial bias have been put in place by ACG. Anyone who refuses to disclose relevant financial relationships will be disqualified. ACG ensures any conflicts of interest are resolved before the educational activity occurs and discloses all relevant financial relationships to the learners prior to the beginning of an education activity.

Commercial Interest

The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services, consumed by, or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

Financial Relationships

Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

Relevant Financial Relationships

The ACCME defines ‘relevant’ financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. The ACCME has not set a minimum dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME considers financial relationships to create actual conflicts of interest in CME when individuals have both a financial relationship with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest.

Conflict of Interest

Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship.

The vast majority of the material presented in the ACG Education Universe has previously been presented in lecture or other learning format, and author disclosure information reflects the content and format for disclosure provided by the presenter as of the date that his/her material was presented and captured electronically, and in compliance with ACG policies and ACCME requirements in effect as of that date of presentation. Author and planner conflicts were identified and resolved in accordance with ACG’s Policies and Procedures on Identifying and Resolving Conflicts of Interest.

Unapproved 'Off-Label' Usage Policy

If any unapproved or off-label use of a product is to be referenced in a CME program presentation, the faculty member shall be required to disclose that the product is either investigational or it is not labeled for the usage being discussed.


David A. Johnson, MD, FACG
Advisory Board: Bovie, Centocor, MedScape, JWatch Gastroenterology, Given
Board of Directors: CRH Medical
Consultant:  Abbvie, Pfizer, Medivo, Medigus, GIdynamics, Epigenomics
Speaker's Bureau: Takeda
Stockholder: Bovie, CRH Medical

Philip O. Katz, MD, FACG
Board of Directors: Esophageal Cancer Action Network

Consultant: Ferring, Ironwood, Medscape, Pfizer Consumer
Royalties: ABIM
Speaker's Bureau: Takeda

Brooks D. Cash, MD, FACG
Consultant: Ironwood, Salix, Sucampo, Takeda, Prometheus, Forest
Speaker's Bureau: Ironwood, Salix, Takeda, Forest

Kenneth R. DeVault, MD, FACG
Board of Directors: Mayo Clinic
Research Grant: Takeda

Seth Gross, MD, FACG
Advisory Board: CDX Diagnostics
Consultant: CSA, Given, Cook
Stockholder: CSA

David T. Rubin, MD, FACG
Advisory Board: CCFA
Consultant: Abbott, Accordant Health, Emmi, Given Imaging, Ironwood, Janssen, Prometheus Laboratories, Santarus Pharmaceuticals, Takeda Pharmaceuticals, Telsar Pharmaceuticals, UCB Pharma, Vertex Pharmaceuticals
Research Support: Abbott, Elan Pharmaceuticals, Warner Chilcott, Prometheus Laboratories, Shire Pharmaceuticals
Board of Directors/Employee: Cornerstones Health Inc.

Mitchell L. Shiffman, MD, FACG
Advisory Board: Abbvie, Achillion, Bayer, BMS, Boerhinger-Ingelheim, Gen Probe, Gilead, GSK, Janssen, Merck, Novartis, Roche/Genentech, Vertex   
Research Support: Abbvie, Achillion, Beckman-Colter, BMS, Boerhinger-Ingelheim, Gen Probe, Gilead, Intercept, Lumena, Mochida, Roche/Genentech
Speaker's Bureau: Bayer, Gilead, Janssen, Roche/Genentech

ACG Board of Trustees

Oversight of all educational programming content is conducted by the ACG Board of Trustees through a review and approval process. View the ACG Board of Trustees disclosure information by clicking on the link below.

2015-2016 ACG Board of Trustees

ACG Staff

All ACG staff in a position to control the content of a CME activity are required to complete ACG’s COI form annually. As of January 2016, all ACG staff in a position to control CME content have nothing to disclose.